Impact of transplant eligibility and availability of a human leukocyte antigen-identical matched related donor on outcome of older patients with acute lymphoblastic leukemia

Leukemia and Lymphoma

Volumn 56, Issue 10, 2015, Pages 2812-2818

  Barba, Pere ^a   Martino, Rodrigo ^b   Martinez Cuadron, David ^c   Olga, García ^d   Esquirol, Albert ^b   Gil Cortés, Cristina ^e   Gonzalez, José ^f   Fernandez Avilés, Francesc ^g   Valcárcel, David ^a   Guardia, Ramón ^h   Duarte, Rafael F ^a   Hernandez Rivas, Jesús Maria ⁱ   Abella, Eugenia ^j   Montesinos, Pau ^c   Ribera, Josep Maria ^d  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^g HOSPITAL CLÍNIC   (Spain)

^h HOSPITAL JOSEP TRUETA   (Spain)

ⁱ CSIC   (Spain)

^j HOSPITAL DEL MAR   (Spain)

more..

Author keywords

acute lymphoblastic leukemia; Allogeneic transplant; HCT; RIC

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; LEUKOCYTE ANTIGEN; MELPHALAN; METHOTREXATE; MYCOPHENOLATE MOFETIL; THIOTEPA; THYMOCYTE ANTIBODY; HLA ANTIGEN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL PROTOCOL; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; HLA TYPING; HUMAN; HUMAN CELL; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; UNRELATED DONORS; ADVERSE EFFECTS; AGE; ALLOTRANSPLANTATION; DONOR; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; MORTALITY; MULTIMODALITY CANCER THERAPY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROCEDURES; RECURRENT DISEASE; RETREATMENT; RISK FACTOR; SIBLING; TREATMENT OUTCOME;

AGE FACTORS; AGED; COMBINED MODALITY THERAPY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; MALE; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; RETREATMENT; RISK FACTORS; SIBLINGS; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84947606450     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2015.1014365     Document Type: Article

References (29)

1. Passweg JR, Baldomero H, Gratwohl A, et al. The EBMT activity survey: 1990-2010. Bone Marrow Transplant 2012;47:906-923.
2. Attal M, Blaise D, Marit G, et al. Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 1995;86: 1619-1628.
3. Gupta V, Richards S, Rowe J. Acute Leukemia Stem Cell Transplantation Trialists' Collaborative Group. Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis. Blood 2013;121:339-350.
4. Hunault M, Harousseau J-L, Delain M, et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood 2004;104:3028-3037.
5. Ribera JM, Oriol A, Morgades M, et al. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 Trial. J Clin Oncol 2014 Apr 21. [Epub ahead of print]
6. Gökbuget N, Kneba M, Raff T, et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood 2012;120:1868-1876.
7. Mohty M, Labopin M, Volin L, et al. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood 2010;116:4439-4443.
8. Marks DI, Wang T, Pérez WS, et al. The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission. Blood 2010;116:366-374.
9. Stein AS, Palmer JM, O'Donnell MR, et al. Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2009;15:1407-1414.
10. Bachanova V, Verneris MR, DeFor T, et al. Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation. Blood 2009;113:2902-2905.
11. Nishiwaki S, Inamoto Y, Imamura M, et al. Reduced-intensity versus conventional myeloablative conditioning for patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in complete remission. Blood 2011;117:3698-3699.
12. Eom K-S, Shin S-H, Yoon J-H, et al. Comparable long-term outcomes after reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for adult high-risk acute lymphoblastic leukemia in complete remission. Am J Hematol 2013;88:634-641.
13. Mitelman F, editor. ISCN: an International System for Human Cytogenetic Nomenclature. Basel, Switzerland: Karger; 1995.
14. Dworzak MN, Gaipa G, Ratei R, et al. Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: multicentric assessment is feasible. Cytometry B Clin Cytom 2008;74:331-340.
15. Ribera J-M, Oriol A, Bethencourt C, et al. Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. Haematologica 2005;90:1346-1356.
16. Sancho J-M, Ribera J-M, Xicoy B, et al. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. Eur J Haematol 2007;78:102-110.
17. Ribera J-M, Oriol A, González M, et al. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. Haematologica 2010;95:87-95.
18. Ribera J-M, García O, Montesinos P, et al. Treatment of young patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia using increased dose of imatinib and deintensified chemotherapy before allogeneic stem cell transplantation. Br J Haematol 2012;159:78-81.
19. Ribera J-M, García O, Fernández-Abellán P, et al. Lack of negative impact of Philadelphia chromosome in older patients with acute lymphoblastic leukaemia in the thyrosine kinase inhibitor era: comparison of two prospective parallel protocols. Br J Haematol 2012;159:485-488.
20. Valcárcel D, Martino R, Caballero D, et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol 2008;26:577-584.
21. Sanz J, Wagner JE, Sanz MA, et al. Myeloablative cord blood transplantation in adults with acute leukemia: comparison of two different transplant platforms. Biol Blood Marrow Transplant 2013;19:1725-1730.
22. Kaplan GL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assoc 1958;53:457-481.
23. Peto R, Pike MC. Conservatism of the approximation (O-E)2/E in the log-rank test for survival data or tumour incidence data. Biometrics 1973;29:579-584.
24. Iacobelli S. Suggestions on the use of statistical methodologies in studies of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2013;48(Suppl. 1):S1-S37.
25. Cox DR. Regression models and life tables. J R Stat Soc B 1972;34:187-220.
26. Doney K, Gooley TA, Deeg HJ, et al. Allogeneic hematopoietic cell transplantation with full-intensity conditioning for adult acute lymphoblastic leukemia: results from a single center, 1998-2006. Biol Blood Marrow Transplant 2011;17:1187-1195.
27. Goldberg JD, Linker A, Kuk D, et al. T cell-depleted stem cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in first complete remission with a decreased risk of graft-versus-host disease. Biol Blood Marrow Transplant 2013;19:208-213.
28. Kako S, Morita S, Sakamaki H, et al. A decision analysis of allogeneic hematopoietic stem cell transplantation in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission who have an HLA-matched sibling donor. Leukemia 2011;25:259-265.
29. Ram R, Storb R, Sandmaier BM, et al. Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia. Haematologica 2011;96:1113-1120.